PALB2 and breast carcinoma: All of the heterozygous germline PALB2 mutations that we detected in advanced breast cancers and familial breast cancers in the Geneplus cohort were high-risk LOF mutations, whereas all of the PALB2 somatic mutations were moderate-risk missense mutations.